OVID

Ovid Therapeutics Inc. (NASDAQ:OVID) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. The company went public in May 2017 and focuses exclusively on developing treatments for rare neurological disorders that primarily affect children and families. Ovid operates as a specialized biotech firm targeting underserved patient populations with significant unmet medical needs, particularly in conditions like fragile X syndrome, tuberous sclerosis complex, and Angelman syndrome.